SYS-CON MEDIA Authors: Pat Romanski, Elizabeth White, Yeshim Deniz, Nikita Ivanov, Sean Houghton

News Feed Item

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users

NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users

http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-fo...

STUDY OBJECTIVES

A drug delivery system is one of the very important aspects in today's growth in the pharmaceutical industry. BCC Research's goal in steering this study is to provide an overview of the current and future characteristics of the market for these drug delivery systems. The key objective is to present a comprehensive analysis and future direction of these drug delivery systems as an important tool in improving the efficacy and safety of the release of drugs in the body.This report explores the present and future strategies within the drug delivery market, which includes sustained release drug delivery, prodrug, implants and intrauterine devices (IUDs), targeted drug delivery, polymeric drug delivery, transdermal drug delivery, and transmucosal drug delivery systems. The improvisation of the market and the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of drug delivery systems are also portrayed in this report.A detailed analysis of drug delivery industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2013 through 2018.Applications for drug delivery systems are also discussed in the report, with emphasis on the usage of these systems in various therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY

Extensive research in the field of various drug delivery systems has revealed their specific functionality in improving the transportation of a pharmaceutical compound in the body as desired to safely achieve its anticipated therapeutic effect. Modern industries have now begun to explore the advantages of these drug delivery systems in their productions and processes. This has led to the steady market for those drug delivery systems.R&D spending, along with increasing competition, patent expiries and new technologies, are directing this in a new direction. The new advancements and new product launches have influenced the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

INTENDED AUDIENCE

This study contributes to the areas of market growth in various drug delivery systems manufacturers and users. Pharmaceutical biotechnical companies and research institutes will find this study to be of interest.

SCOPE OF THE STUDY

The scope of this study encompasses drug delivery systems in pharmaceutical and biotechnology markets. BCC Research analyzes each market by its type, region and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The emerging markets for drug delivery systems include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and so forth.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC Research conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with manufacturers of drug delivery systems and technical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, new developments and market trends.

INFORMATION SOURCES

Many companies were surveyed to obtain data for this study. Included were manufacturers and end users of drug delivery systems in therapeutic categories and various disease sectors industries. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years' of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC Research are: Reagents for Chromatography; Spectroscopy: An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

REPORT HIGHLIGHTS

The global revenue for advanced drug delivery systems is estimated to be $181.9 billion in 2013. In 2018, revenues are estimated to reach $212.8 billion, demonstrating a compound annual growth rate (CAGR) of 3.2%.This report provides:• An overview of the global market for drug delivery systems, with a focus on the end users.• Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.• Discussion of the current state, setbacks, innovations, and the future needs of the market.• Analyses of the regulatory environment and the technology involved, including the latest developments.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY OBJECTIVES 2REASONS FOR DOING THIS STUDY 2INTENDED AUDIENCE 3SCOPE OF THE STUDY 3METHODOLOGY 3INFORMATION SOURCES 3ABOUT THE AUTHOR 3RELATED BCC RESEARCH REPORTS 4BCC RESEARCH ONLINE SERVICES 4DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BYREGION, THROUGH 2018 ($ MILLIONS) 7SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BYREGION, 2011-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 9

NEED FOR THE DOSAGE FORMS 9TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY 11SUSTAINED RELEASE DRUG DELIVERY 11Oral Sustained Release Drug Delivery 11Intramuscular (IM) Injections or Microsyringes 12TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUGDELIVERY 12PRODRUGS 13Subtypes of Prodrugs 14TABLE 3 CLASSIFICATION OF PRODRUGS 14Need for Prodrugs 15TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15IMPLANTS AND INTRAUTERINE DEVICES (IUDS) 16Copper-based Devices 16Hormonal-based Devices 16Mechanism 17TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17TARGETED DRUG DELIVERY 18Delivery Vehicles 18Liposomes 18TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19Micelles and Dendrimers 19Mechanisms of Drug Delivery 19Advantages of Dendrimers 20Biodegradable Particles 20Artificial DNA Nanostructures 20Monoclonal Antibodies 21Applications 21TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22POLYMERIC DRUG DELIVERY 22Applications of Polymers in Drug Delivery 22TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23Pegylation 23TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24Future Perspectives 24CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION 24ORAL DRUG DELIVERY 24TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25INJECTABLE OR PARENTERAL DRUG DELIVERY 25TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25PULMONARY DRUG DELIVERY 26TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26NASAL DRUG DELIVERY 27TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27ORAL MUCOSAL DRUG DELIVERY 27TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUGDELIVERY 28RECTAL DRUG DELIVERY 28TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28OCULAR DRUG DELIVERY 29TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29TRANSDERMAL DRUG DELIVERY 29TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29

CHAPTER 4 REGULATORY ASPECTS 32

NEW PRODUCTS APPROVED IN 2009-2013 32TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32FDA RECALLS AND SAFETY ALERTS 35TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37

CHAPTER 5 NEW DEVELOPMENTS 40

NEW PARTNERSHIPS, MERGERS AND ACQUISITION 40TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41NEW PRODUCTS 42TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43PIPELINE PRODUCTS 44TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44

CHAPTER 6 GLOBAL MARKETS 47

MARKET BY TYPE 47MARKET OVERVIEW 47MARKET REVENUE 50TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH2018 ($ MILLIONS) 50FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($MILLIONS) 50MARKET SHARE 51TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 52MARKET BY REGION 52SUSTAINED RELEASE DRUG DELIVERY SYSTEM 52Market Overview 53Market Revenue 54TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 54FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 54Market Share 55TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,FOR 2012 (%) 55FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,FOR 2012 (%) 55PRODRUGS 55Market Overview 56Market Revenue 56TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 56FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 56Market Share 57TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 57FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 57IMPLANTS AND IUDS 58Market Overview 58Market Revenue 58TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018($ MILLIONS) 59FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($MILLIONS) 59Market Share 59TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60TRANSMUCOSAL DELIVERY SYSTEMS 60Market Overview 61Market Revenue 63TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 63FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 63Market Share 64TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012(%) 64FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012(%) 64TARGETED DRUG DELIVERY 64Market Overview 65Market Revenue 66TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH2018 ($ MILLIONS) 66FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 66Market Share 67TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67TRANSDERMAL DRUG DELIVERY SYSTEM 67Market Overview 68Market Revenue 68TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 68FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 69Market Share 69TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,2012 ($ MILLIONS) 69FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BYREGION, 2012 (%) 69POLYMERIC DRUG DELIVERY 70Market Overview 70Market Revenue 71TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,THROUGH 2018 ($ MILLIONS) 71FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,2011-2018 ($ MILLIONS) 71Market Share 72TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72MARKET BY END USERS 72MARKET OVERVIEW 73MARKET REVENUE 77TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, THROUGH 2018 ($ MILLIONS) 78FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, 2011-2018 ($ MILLIONS) 78MARKET SHARE 79TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,2012 (%) 80FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,2012 (%) 80

CHAPTER 7 MARKET BY END USERS 82

TABLE 42 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, THROUGH 2018 ($ MILLIONS) 83FIGURE 19 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BYAPPLICATIONS, 2011-2018 ($ MILLIONS) 83CARDIOVASCULAR DISEASES 84MARKET REVENUE 85TABLE 43 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,THROUGH 2018 ($ MILLIONS) 85FIGURE 20 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,2011-2018 ($ MILLIONS) 85MARKET SHARE 86TABLE 44 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BYREGION, 2012 (%) 86FIGURE 21 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BYREGION, 2012 (%) 86ONCOLOGY 87MARKET REVENUE 88TABLE 45 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH2018 ($ MILLIONS) 88FIGURE 22 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS,2011-2018 ($ MILLIONS) 88MARKET SHARE 89TABLE 46 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 89FIGURE 23 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 89GASTROINTESTINAL SYSTEMS 89MARKET REVENUE 90TABLE 47 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,THROUGH 2018 ($ MILLIONS) 90FIGURE 24 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,2011-2018 ($ MILLIONS) 90MARKET SHARE 91TABLE 48 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERYSYSTEMS, 2012 (%) 91FIGURE 25 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERYSYSTEMS, 2012 (%) 91UROLOGY 92MARKET REVENUE 93TABLE 49 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH2018 ($ MILLIONS) 93FIGURE 26 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018($ MILLIONS) 93MARKET SHARE 93TABLE 50 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 94FIGURE 27 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 94DIABETES 94MARKET REVENUE 95TABLE 51 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH2018 ($ MILLIONS) 95FIGURE 28 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES,2011-2018 ($ MILLIONS) 95MARKET SHARE 96TABLE 52 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,2012 (%) 96FIGURE 29 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,2012 (%) 96CENTRAL NERVOUS SYSTEM 97MARKET REVENUE 97TABLE 53 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERYSYSTEMS, THROUGH 2018 ($ MILLIONS) 98FIGURE 30 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERYSYSTEMS, 2011-2018 ($ MILLIONS) 98MARKET SHARE 98TABLE 54 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERYSYSTEMS BY REGION, 2012 (%) 99FIGURE 31 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERYSYSTEMS BY REGION, 2012 (%) 99RESPIRATORY DRUG DELIVERY SYSTEMS 99MARKET REVENUE 100TABLE 55 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,THROUGH 2018 ($ MILLIONS) 100FIGURE 32 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,2011-2018 ($ MILLIONS) 100MARKET SHARE 101TABLE 56 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 101FIGURE 33 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,2012 (%) 101INFLAMMATORY DISEASES AND ALLERGIES 101MARKET REVENUE 102TABLE 57 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORYDISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS) 102FIGURE 34 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORYDISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS) 102MARKET SHARE 103TABLE 58 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORYDISEASES AND ALLERGIES BY REGION, 2012 (%) 103FIGURE 35 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORYDISEASES AND ALLERGIES BY REGION, 2012 (%) 103OPHTHALMOLOGY 104MARKET REVENUE 105TABLE 59 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,THROUGH 2018 ($ MILLIONS) 105FIGURE 36 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,2011-2018 ($ MILLIONS) 105MARKET SHARE 106TABLE 60 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BYREGION, 2012 (%) 106FIGURE 37 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BYREGION, 2012 (%) 106VIRAL AND BACTERIAL DISEASES 107MARKET REVENUE 107TABLE 61 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL ANDBACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS) 107FIGURE 38 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL ANDBACTERIAL DISEASES, 2011-2018 ($ MILLIONS) 108MARKET SHARE 108TABLE 62 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL ANDBACTERIAL DISEASES BY REGION, 2012 (%) 108FIGURE 39 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL ANDBACTERIAL DISEASES BY REGION, 2012 (%) 108HORMONE REPLACEMENT THERAPY AND GYNECOLOGY 109MARKET REVENUE 110TABLE 63 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONEREPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS) 110FIGURE 40 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONEREPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS) 110MARKET SHARE 111TABLE 64 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONEREPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 111FIGURE 41 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONEREPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 111OTHERS 112MARKET REVENUE 113TABLE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,THROUGH 2018 ($ MILLIONS) 113FIGURE 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,2911-2018 ($ MILLIONS) 113MARKET SHARE 114TABLE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012(%) 114FIGURE 43 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES,2012 (%) 114MARKET SHARE OF APPLICATIONS 114TABLE 67 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012(%) 114FIGURE 44 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012(%) 115

CHAPTER 8 PATENT ANALYSIS 117

PATENTS BY YEAR 117TABLE 68 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009–JULY 2013 117FIGURE 45 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 117PATENTS BY CATEGORY 118TABLE 69 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 118FIGURE 46 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 119PATENTS BY TYPE 119TABLE 70 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 119PATENTS BY COMPANY 120TABLE 71 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 120PATENTS BY COUNTRY 122TABLE 72 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 122PATENTS BY ASSIGNEE 123TABLE 73 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 123FIGURE 47 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 123

CHAPTER 9 CURRENT SITUATION 125

CHAPTER 10 COMPANY PROFILES 129

3M COMPANY 129

ABBOTT LABORATORIES 129

ACTAVIS INC. 130

AKELA PHARMA INC. 130

AKORN, INC. 131

ALCON INC. 131

ALEXION PHARMACEUTICALS, INC. 132

ALKERMES 132

ALLERGAN INC. 132

AMGEN INC. 133

A.P. PHARMA 134

APTALIS PHARMA INC. 134

ASTELLAS PHARMA INC. 135

ASTRAZENECA PLC 135

ATON PHARMA 136

BAUSCH & LOMB 136

BAXTER INTERNATIONAL INC. 136

BAYER HEALTHCARE PHARMACEUTICALS 137

BIOGEN IDEC 137

BIOSANTE PHARMACEUTICALS, INC. 138

BOEHRINGER INGELHEIM 138

BOSTON SCIENTIFIC 139

BRISTOL MYERS SQUIBB 139

CELGENE CORPORATION 140

CEPHALON, INC. 140

COLUMBIA LABORATORIES, INC. 141

EISAI CO., LTD 141

ELAN DRUG TECHNOLOGIES 142

ENZON PHARMACEUTICALS 142

GENENTECH INC. 143

GENEREX BIOTECHNOLOGY CORPORATION 143

GENZYME CORPORATION 144

GILEAD SCIENCES, INC. 145

GLAXOSMITHKLINE PLC 145

HISAMITSU PHARMACEUTICAL CO., INC. 146

IMCLONE SYSTEMS INC. 146

JANSSEN BIOTECH, INC. 147

JOHNSON & JOHNSON 147

KEMPHARM, INC. 148

K.V. PHARMACEUTICAL CO. 148

LAVIPHARM CORPORATION 149

MANNKIND CORPORATION 149

MERCK & CO. 150

MYLAN LABORATORIES INC. 150

NEKTAR THERAPEUTICS 151

NEUROGESX INC. 151

NEWGEN BIOPHARMA 152

NOVARTIS AG 152

NOVAVAX, INC. 153

NOVEN PHARMACEUTICALS, INC. 153

NYCOMED US INC. 154

OSI PHARMACEUTICALS, INC. 154

PAR PHARMACEUTICAL COMPANIES, INC. 155

PDL BIOPHARMA, INC. 155

PFIZER INC. 156

QLT INC. 156

ROCHE HOLDING AG 157

SANOFI SA 157

TEVA PHARMACEUTICAL INDUSTRIES LTD. 158

THERAJECT, INC. 159

UMEWORLD LTD. 159

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. 160

XEL PHARMACEUTICALS, INC. 160

CHAPTER 11 APPENDIX I 162LIST OF TABLES

SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY

REGION, THROUGH 2018 ($ MILLIONS) 7

TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY 10

TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG

DELIVERY 12

TABLE 3 CLASSIFICATION OF PRODRUGS 14

TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS 15

TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS 17

TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES 19

TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES 22

TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS 23

TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION 24

TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY 25

TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY 25

TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY 26

TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY 27

TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY 28

TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY 28

TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY 29

TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY 29

TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013 32

TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013 35

TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013 37

TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013 41

TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013 43

TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET 44

TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018

($ MILLIONS) 50

TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 51

TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 54

TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

FOR 2012 (%) 55

TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 56

TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%) 57

TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 ($

MILLIONS) 59

TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60

TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 63

TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%) 64

TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 66

TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67

TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

THROUGH 2018 ($ MILLIONS) 68

TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION,

2012 ($ MILLIONS) 69

TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH

2018 ($ MILLIONS) 71

TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72

TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

THROUGH 2018 ($ MILLIONS) 78

TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

2012 (%) 80

TABLE 42 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

THROUGH 2018 ($ MILLIONS) 83

TABLE 43 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,

THROUGH 2018 ($ MILLIONS) 85

TABLE 44 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY

REGION, 2012 (%) 86

TABLE 45 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH

2018 ($ MILLIONS) 88

TABLE 46 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 89

TABLE 47 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,

THROUGH 2018 ($ MILLIONS) 90

TABLE 48 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY

SYSTEMS, 2012 (%) 91

TABLE 49 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH

2018 ($ MILLIONS) 93

TABLE 50 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012

(%) 94

TABLE 51 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH

2018 ($ MILLIONS) 95

TABLE 52 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,

2012 (%) 96

TABLE 53 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY

SYSTEMS, THROUGH 2018 ($ MILLIONS) 98

TABLE 54 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY

SYSTEMS BY REGION, 2012 (%) 99

TABLE 55 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH

2018 ($ MILLIONS) 100

TABLE 56 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 101

TABLE 57 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY

DISEASES AND ALLERGIES, THROUGH 2018 ($ MILLIONS) 102

TABLE 58 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY

DISEASES AND ALLERGIES BY REGION, 2012 (%) 103

TABLE 59 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,

THROUGH 2018 ($ MILLIONS) 105

TABLE 60 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY

REGION, 2012 (%) 106

TABLE 61 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND

BACTERIAL DISEASES, THROUGH 2018 ($ MILLIONS) 107

TABLE 62 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL

DISEASES BY REGION, 2012 (%) 108

TABLE 63 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE

REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 ($ MILLIONS) 110

TABLE 64 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE

REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 111

TABLE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,

THROUGH 2018 ($ MILLIONS) 113

TABLE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012

(%) 114

TABLE 67 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%) 114

TABLE 68 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009–JULY 2013 117

TABLE 69 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 118

TABLE 70 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013 119

TABLE 71 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013 120

TABLE 72 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013 122

TABLE 73 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 123

LIST OF FIGURES

SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS,BY

REGION, 2011-2018 ($ MILLIONS) 7

FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 ($

MILLIONS) 50

FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%) 52

FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 54

FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, FOR

2012 (%) 55

FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018

($ MILLIONS) 56

FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%) 57

FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 ($

MILLIONS) 59

FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%) 60

FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 63

FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012

(%) 64

FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 66

FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%) 67

FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 69

FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 69

FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION,

2011-2018 ($ MILLIONS) 71

FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%) 72

FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY

APPLICATIONS, 2011-2018 ($ MILLIONS) 78

FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS,

2012 (%) 80

FIGURE 19 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY

APPLICATIONS, 2011-2018 ($ MILLIONS) 83

FIGURE 20 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,

2011-2018 ($ MILLIONS) 85

FIGURE 21 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY

REGION, 2012 (%) 86

FIGURE 22 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2011-2018

($ MILLIONS) 88

FIGURE 23 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 89

FIGURE 24 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,

2011-2018 ($ MILLIONS) 90

FIGURE 25 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY

SYSTEMS, 2012 (%) 91

FIGURE 26 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018

($ MILLIONS) 93

FIGURE 27 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 94

FIGURE 28 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES,

2011-2018 ($ MILLIONS) 95

FIGURE 29 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION,

2012 (%) 96

FIGURE 30 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY

SYSTEMS, 2011-2018 ($ MILLIONS) 98

FIGURE 31 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY

SYSTEMS BY REGION, 2012 (%) 99

FIGURE 32 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS,

2011-2018 ($ MILLIONS) 100

FIGURE 33 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION,

2012 (%) 101

FIGURE 34 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY

DISEASES AND ALLERGIES, 2011-2018 ($ MILLIONS) 102

FIGURE 35 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY

DISEASES AND ALLERGIES BY REGION, 2012 (%) 103

FIGURE 36 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,

2011-2018 ($ MILLIONS) 105

FIGURE 37 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY

REGION, 2012 (%) 106

FIGURE 38 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND

BACTERIAL DISEASES, 2011-2018 ($ MILLIONS) 108

FIGURE 39 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND

BACTERIAL DISEASES BY REGION, 2012 (%) 108

FIGURE 40 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE

REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 ($ MILLIONS) 110

FIGURE 41 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE

REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%) 111

FIGURE 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES,

2911-2018 ($ MILLIONS) 113

FIGURE 43 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012

(%) 114

FIGURE 44 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012

(%) 115

FIGURE 45 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013 117

FIGURE 46 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013 119

FIGURE 47 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013 123

To order this report: Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
There's Big Data, then there's really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at Big Data Expo®, Hannah Smalltree, Director at Treasure Data, discussed how IoT, Big D...
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the ...
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's large...
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at Internet of @ThingsExpo, James Kirkland, Chief Ar...
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective ...
Scott Jenson leads a project called The Physical Web within the Chrome team at Google. Project members are working to take the scalability and openness of the web and use it to talk to the exponentially exploding range of smart devices. Nearly every company today working on the IoT comes up with the same basic solution: use my server and you'll be fine. But if we really believe there will be trillions of these devices, that just can't scale. We need a system that is open a scalable and by using ...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
"SAP had made a big transition into the cloud as we believe it has significant value for our customers, drives innovation and is easy to consume. When you look at the SAP portfolio, SAP HANA is the underlying platform and it powers all of our platforms and all of our analytics," explained Thorsten Leiduck, VP ISVs & Digital Commerce at SAP, in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SAP is delivering break-through innovation combined with fantastic user experience powered by the market-leading in-memory technology, SAP HANA. In his General Session at 15th Cloud Expo, Thorsten Leiduck, VP ISVs & Digital Commerce, SAP, discussed how SAP and partners provide cloud and hybrid cloud solutions as well as real-time Big Data offerings that help companies of all sizes and industries run better. SAP launched an application challenge to award the most innovative SAP HANA and SAP HANA...
Fundamentally, SDN is still mostly about network plumbing. While plumbing may be useful to tinker with, what you can do with your plumbing is far more intriguing. A rigid interpretation of SDN confines it to Layers 2 and 3, and that's reasonable. But SDN opens opportunities for novel constructions in Layers 4 to 7 that solve real operational problems in data centers. "Data center," in fact, might become anachronistic - data is everywhere, constantly on the move, seemingly always overflowing. Net...
What do a firewall and a fortress have in common? They are no longer strong enough to protect the valuables housed inside. Like the walls of an old fortress, the cracks in the firewall are allowing the bad guys to slip in - unannounced and unnoticed. By the time these thieves get in, the damage is already done and the network is already compromised. Intellectual property is easily slipped out the back door leaving no trace of forced entry. If we want to reign in on these cybercriminals, it's hig...